Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
Company profile
Ticker
FATE
Exchange
Website
CEO
John Wolchko
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
SEC CIK
Corporate docs
Subsidiaries
Fate Therapeutics (UK) Ltd. • Tfinity Therapeutics, Inc. • Fate Therapeutics B.V. • Senescea Therapeutics, Inc. ...
FATE stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-K
2022 FY
Annual report
28 Feb 23
8-K
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
28 Feb 23
8-K
Termination of a Material Definitive Agreement
5 Jan 23
8-K
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
7 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
3 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
3 Aug 22
8-K
ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration
30 Jun 22
8-K
Departure of Directors or Certain Officers
13 Jun 22
Transcripts
FATE
Earnings call transcript
2022 Q4
28 Feb 23
FATE
Earnings call transcript
2022 Q3
4 Nov 22
FATE
Earnings call transcript
2022 Q2
4 Aug 22
FATE
Earnings call transcript
2022 Q1
5 May 22
FATE
Earnings call transcript
2021 Q4
1 Mar 22
FATE
Earnings call transcript
2021 Q3
5 Nov 21
FATE
Earnings call transcript
2021 Q2
5 Aug 21
FATE
Earnings call transcript
2021 Q1
6 May 21
FATE
Earnings call transcript
2020 Q4
25 Feb 21
FATE
Earnings call transcript
2020 Q3
6 Nov 20
Latest ownership filings
SC 13G
MILLENNIUM MANAGEMENT LLC
22 Mar 23
SC 13G/A
VANGUARD GROUP INC
10 Mar 23
SC 13G
Capital World Investors
13 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
4
J Scott Wolchko
7 Feb 23
4
Bahram Valamehr
7 Feb 23
4
CINDY TAHL
7 Feb 23
4
Brian T. Powl
7 Feb 23
4
Edward J Dulac III
7 Feb 23
4
Yu-Waye Chu
7 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 76.56 mm | 76.56 mm | 76.56 mm | 76.56 mm | 76.56 mm | 76.56 mm |
| Cash burn (monthly) | 6.92 mm | 6.02 mm | 21.47 mm | 25.70 mm | 25.13 mm | 20.68 mm |
| Cash used (since last report) | 20.44 mm | 17.78 mm | 63.42 mm | 75.90 mm | 74.22 mm | 61.09 mm |
| Cash remaining | 56.12 mm | 58.78 mm | 13.14 mm | 656.84 k | 2.34 mm | 15.47 mm |
| Runway (months of cash) | 8.1 | 9.8 | 0.6 | 0.0 | 0.1 | 0.7 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 221 |
| Opened positions | 34 |
| Closed positions | 47 |
| Increased positions | 94 |
| Reduced positions | 58 |
| 13F shares | Current |
|---|---|
| Total value | 1.06 tn |
| Total shares | 105.60 mm |
| Total puts | 83.80 k |
| Total calls | 86.30 k |
| Total put/call ratio | 1.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Redmile | 12.96 mm | $130.74 bn |
| BLK Blackrock | 9.73 mm | $98.14 bn |
| Vanguard | 7.97 mm | $80.44 bn |
| STT State Street | 5.94 mm | $59.89 bn |
| Capital World Investors | 5.59 mm | $56.42 bn |
| BLVGF Bellevue | 4.86 mm | $49.05 bn |
| ARK Investment Management | 4.21 mm | $42.53 bn |
| JNJ Johnson & Johnson | 3.38 mm | $34.09 bn |
| Millennium Management | 2.86 mm | $28.90 bn |
| T. Rowe Price | 2.66 mm | $26.83 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 Feb 23 | Yu-Waye Chu | Stock Option Common Stock | Grant | Acquire A | No | No | 6.77 | 425,000 | 2.88 mm | 425,000 |
| 6 Feb 23 | Edward J Dulac III | Stock Option Common Stock | Grant | Acquire A | No | No | 6.77 | 425,000 | 2.88 mm | 425,000 |
| 6 Feb 23 | Brian T. Powl | Stock Option Common Stock | Grant | Acquire A | No | No | 6.77 | 425,000 | 2.88 mm | 425,000 |
| 6 Feb 23 | Cindy Tahl | Stock Option Common Stock | Grant | Acquire A | No | No | 6.77 | 425,000 | 2.88 mm | 425,000 |
| 6 Feb 23 | Bahram Valamehr | Stock Option Common Stock | Grant | Acquire A | No | No | 6.77 | 450,000 | 3.05 mm | 450,000 |
News
15 Analysts Have This to Say About Fate Therapeutics
27 Mar 23
Wells Fargo Assumes Fate Therapeutics at Equal-Weight, Announces Price Target of $6
27 Mar 23
Citigroup Maintains Buy on Fate Therapeutics, Raises Price Target to $10
2 Mar 23
Expert Ratings for Fate Therapeutics
1 Mar 23
EF Hutton Reiterates Buy on Fate Therapeutics, Maintains $10 Price Target
1 Mar 23
Press releases
FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE
22 Mar 23
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fate Therapeutics, Inc. (FATE) Investors of Class Action and Last Few Hours to Actively Participate
22 Mar 23
Fate Class Action: Levi & Korsinsky Reminds Fate Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 22, 2023 - FATE
22 Mar 23
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
22 Mar 23
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)
22 Mar 23